Clinical Trial

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-12-27; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT06752356
Lead Sponsor Kedrion S.p.A.
Conditions Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 161 participants
Start Date 2026-08
Primary Completion 2027-12-20 (estimated)
Study Completion 2027-12-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-06